The latest announcement is out from CSPC Pharmaceutical Group ( (HK:1093) ).
CSPC Pharmaceutical Group Limited has announced that its herpes zoster mRNA vaccine, SYS6017, has received clinical trial approval from China’s National Medical Products Administration. This vaccine, which targets the varicella-zoster virus, is designed to prevent herpes zoster infections and shows potential for a lower incidence of adverse reactions. Currently, no mRNA vaccines for VZV infections are available on the global market, placing CSPC in a potentially advantageous position to address this unmet medical need.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a company incorporated in Hong Kong, operating in the pharmaceutical industry. The company focuses on the development and distribution of pharmaceutical products, including innovative drug formulations and vaccines.
YTD Price Performance: -0.51%
Average Trading Volume: 8,854
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.76B
For detailed information about 1093 stock, go to TipRanks’ Stock Analysis page.